Advanced in Clear Cell Sarcoma

Dr. John Sarantopoulos

Hematology | Oncology
The University Of Texas Health Science Center At San Antonio
7703 Floyd Curl Dr, Suite Mc7977, 
San Antonio, TX 
Offers Telehealth
Advanced in Clear Cell Sarcoma
The University Of Texas Health Science Center At San Antonio
7703 Floyd Curl Dr, Suite Mc7977, 
San Antonio, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

John Sarantopoulos is a Hematologist and an Oncologist in San Antonio, Texas. Dr. Sarantopoulos is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Renal Cell Carcinoma (RCC), ALK-Positive Non-Small Cell Lung Cancer, and Lung Adenocarcinoma.

His clinical research consists of co-authoring 66 peer reviewed articles and participating in 18 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in TX
Hospital Affiliations
University Health System
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community First Health Plans
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7703 Floyd Curl Dr, Suite Mc7977, San Antonio, TX 78229
Other Locations
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO
7979 Wurzbach Rd, San Antonio, TX 78229

Additional Areas of Focus

Dr. Sarantopoulos has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
A Phase 1b Biomarker-Driven Combination Trial of Copanlisib, Olaparib, and Durvalumab (MEDI4736) in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Procedure, Drug, Biological
Study Phase: Phase 1
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
A Phase 1 Study of Pembrolizumab (MK-3475) in Combination With Recombinant Interleukin-12 in Patients With Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Biological
Study Phase: Phase 1
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors
A Phase 1a/1b, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Evidence of Antitumor Activity of INV-1120 As a Single Agent and in Combination with Pembrolizumab in Adult Patients with Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2024
Intervention Type: Drug, Combination product
Study Phase: Phase 1
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib in Patients With Metastatic Castration-resistant Prostate Cancer Following Standard of Care Treatment
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Drug
Study Drugs: LAE001, Prednisone, Afuresertib
Study Phase: Phase 1/Phase 2
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
A Randomized Phase II Study of Co-Expression Extrapolation (COXEN) With Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drugs: Gemcitabine, Cisplatin, Methotrexate, Vinblastine, Doxorubicin, Filgrastim
Study Phase: Phase 2
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drugs: BLZ945, PDR001
Study Phase: Phase 1/Phase 2
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 06, 2023
Intervention Type: Drug
Study Drugs: MBG453, PDR001, Decitabine
Study Phase: Phase 1/Phase 2
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
A Phase 1a / 1b, First-in-human, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0903 Administered Daily for 21 Days to Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: TP-0903
Study Phase: Phase 1
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors
Phase I Dose-Finding, Safety Study of Oral AMXT 1501 Dicaprate and Difluoromethylornithine (DFMO) in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: May 25, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: March 02, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Enrollment Status: Completed
Publish Date: January 11, 2023
Intervention Type: Drug, Biological
Study Drugs: PDR001, LCL161, Everolimus, Panobinostat, QBM076, HDM201
Study Phase: Phase 1
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies
Enrollment Status: Completed
Publish Date: February 10, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors
A Phase 1 Multi-center, Open-label Dose Escalation and Expansion Study of PCA062 Administered Intravenously in Adult Patients With p-CAD Positive Tumors
Enrollment Status: Completed
Publish Date: December 19, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
A Phase I, First-in-Human, Dose Escalation Trial of MSC2363318A, a Dual p70S6K/Akt Inhibitor, in Subjects With Advanced Malignancies
Enrollment Status: Completed
Publish Date: September 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
A Phase 1 Trial of SGN-CD70A in Patients With CD70-Positive Malignancies
Enrollment Status: Completed
Publish Date: April 19, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 17 Less Clinical Trials

66 Total Publications

Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors.
Journal: Cancer research communications
Published: February 12, 2025
Similar Doctors
Distinguished in Clear Cell Sarcoma
Dr. Rebecca E. Barrington
Oncology | Hematology Oncology
Distinguished in Clear Cell Sarcoma
Dr. Rebecca E. Barrington
Oncology | Hematology Oncology

Texas Oncology PA

694 Hill Country Dr, 
Kerrville, TX 
 (50.5 miles away)
830-792-3434
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rebecca Barrington is an Oncologist and a Hematologist Oncology provider in Kerrville, Texas. Dr. Barrington is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Paget Disease of the Breast, Large-Cell Immunoblastic Lymphoma, Colorectal Cancer, and Childhood Iron Deficiency Anemia. Dr. Barrington is currently accepting new patients.

Advanced in Clear Cell Sarcoma
Dr. Alyssa G. Rieber
Hematology Oncology | Oncology | Hematology
Advanced in Clear Cell Sarcoma
Dr. Alyssa G. Rieber
Hematology Oncology | Oncology | Hematology

Texas Oncology PA

506 W Windcrest St, Suite 300, 
Fredericksburg, TX 
 (55.5 miles away)
830-990-0255
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alyssa Rieber is a Hematologist Oncology specialist and an Oncologist in Fredericksburg, Texas. Dr. Rieber is rated as a Distinguished provider by MediFind in the treatment of Clear Cell Sarcoma. Her top areas of expertise are Upper Tract Urothelial Carcinoma (UTUC), Breast Cancer, Paget Disease of the Breast, and Pleuropulmonary Blastoma. Dr. Rieber is currently accepting new patients.

Advanced in Clear Cell Sarcoma
Dr. Vijay K. Gunuganti
Oncology
Advanced in Clear Cell Sarcoma
Dr. Vijay K. Gunuganti
Oncology

Texas Oncology PA

18707 Hardy Oak Blvd, Suite 320, 
San Antonio, TX 
 (9.6 miles away)
210-545-6972
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Vijay Gunuganti is an Oncologist in San Antonio, Texas. Dr. Gunuganti is rated as an Advanced provider by MediFind in the treatment of Clear Cell Sarcoma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Multiple Myeloma, Lung Cancer, and Renal Cell Carcinoma (RCC). Dr. Gunuganti is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sarantopoulos's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 53 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile